Quo vadis, PFAS? Positions and perspectives for medical technology.

The proposed restriction on perfluorinated and polyfluorinated alkyl substances, PFAS for short, poses a dilemma for medical technology. On the one hand, it has not yet been decided what the future holds for fluoropolymers in the EU, for example. On the other hand, companies already have to make far-reaching strategic decisions. Should they - or can they - remove, replace or keep the substances? The panel will examine the status of the process, the use of PFAS in medical technology, the search for alternatives and possible scenarios in the event of a restriction from the perspective of industry, research and politics.

Moderation: Yvonne Glienke (Managing Director MedicalMountains GmbH)

Please note: the panel discussion will be held in German.

Supported by: MedicalMountains GmbH